

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

HYDRON TECHNOLOGIES INC
Form 10-K
April 03, 2001

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K
FOR ANNUAL AND TRANSITION REPORTS
PURSUANT TO SECTIONS 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

(Mark One)

Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Fiscal year ended DECEMBER 31, 2000 or

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____.

Commission file Number 0-6333

HYDRON TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

New York

13-1574215

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

1001 Yamato Road, Suite 403, Boca Raton, Florida

33431

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (561) 994-6191

Securities registered pursuant to Section 12(b) of the Act: NONE

Securities registered pursuant to Section 12(g) of the Act:
COMMON STOCK, PAR VALUE \$.01 PER SHARE

(Title of Class)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES NO

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any other amendment to this Form 10-K.

The aggregate market value of the voting stock held by non-affiliates of the Registrant was \$864,906 based upon the closing price of \$0.19 on March

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

15, 2001.

Number of shares of Common Stock outstanding as of March 15, 2001: 4,975,136

Documents Incorporated by Reference: NONE

PART I

ITEM 1. BUSINESS

Introduction

Hydron Technologies, Inc. ("the Company"), a New York corporation organized on January 30, 1948, maintains its principal office at 1001 Yamato Road, Suite 403, Boca Raton, Florida 33431 and its telephone number is (561) 994-6191.

The Company markets a broad range of consumer and oral health care products using a moisture-attracting ingredient (the "Hydron(R) polymers"), and owns a non-prescription drug delivery system for topically applied pharmaceuticals, which uses such polymer. The Company holds U.S. and international patents on, what Management believes is, the only known cosmetically acceptable method to suspend the Hydron polymer in a stable emulsion for use in personal care/cosmetic products. The Company has concentrated its sales and development activities primarily on the application of these biocompatible, hydrophilic polymers in various personal care/cosmetic products for consumers and, to a lesser extent, oral care products for dental professionals. The Company is developing other personal care/cosmetic products for consumers using its patented technology. The Company intends to continue to explore the efficacy of using its technology as a topical drug delivery system and would, when appropriate, either seek licensing arrangements with third parties, or develop and market proprietary products through its own efforts. Management believes that, because of their unique properties, products that utilize Hydron polymers have the potential for wide acceptance in consumer and professional health care markets.

Consumer Products

The Company has been engaged in the development of various consumer products using Hydron polymers since 1986. The Company's products are designed to address concerns about aging, and include Hydron skin care, hair care, bath and body and sun care.

The Company currently has thirty-nine individual products available in the following product lines: skin care (22 products), hair care (7 products), bath and body (8 products) and sun care (2 products). These products are also packaged into collections and sold at a higher value. A number of the products are presently being sold to and marketed by Home Shopping Club LP ("HSN") and its subsidiary Home Shopping Espanol (HSE). All of the products are sold directly by the Company to consumers through the Company's Hydron Catalog and Website WWW.HYDRON.COM ("Catalog").

Management believes that the Company's product lines are unique and offer the following competitive benefits: the moisturizers self-adjust to match the skin's optimal pH balance soon after they are applied to the skin; they become water-insoluble on the skin's surface, and unlike all other water-based cremes and lotions, are not removed by the skin's perspiration or plain water;

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

they are oxygen-permeable, allow the skin to breathe and leave no greasy after-feel; they do not emulsify the skin's natural moisturizing agents, as do conventional cremes and lotions; and they attract and hold water, creating a cushion of moisture on the skin's surface that promotes penetration of other beneficial product ingredients. The Company's products are dermatologist tested and approved for all skin types. Products for use around the eye area are also ophthalmologist tested and safe for contact lens wearers. Most of the Company's moisturizing products are based on the Company's patented emulsion system, which permits the product ingredients to deliver their intended benefits over an extended period of time and in a more efficient manner. See "Patented Technology."

Professional Products

The Company has also developed and markets a group of Hydron polymer-based products for dental professionals under the Hydrocryl(R) brand name. These include a heat cured material used in the manufacture of dentures, as well as cold cure kits used in connection with the relining or repairing of existing Hydrocryl or conventional acrylic dentures that is necessitated by the continual changes that occur in the tissue structure of the mouth. Management believes that the hydrophilic, or moisture attracting properties, of these Hydron polymer-based products give them competitive advantages over conventional acrylic dentures and denture repair kits, which are not hydrophilic. Sales of Hydrocryl brand name products were minimal in Fiscal 2000, Fiscal 1999 and Fiscal 1998.

Topical Drug Delivery System

Management believes that the Company's patented Hydron emulsion system can enhance the effectiveness of over-the-counter medications applied to the skin. The system is designed to deposit a uniform film on the skin's surface and to have a relatively low affinity for the drug associated with the application. The emulsion system is moisture-resistant so that it is not degraded by perspiration or sebaceous oils, but is oxygen permeable. Management believes that the Hydron system has a number of advantages over traditional lotions as it promotes hydration of the stratum corneum, which improves penetration into the skin's pores, and has good tactility and flexibility. The system has also been developed to be free from greasiness, brittleness, tackiness, gumminess or oiliness, to make it comfortable on the skin and to be resistant to inks, dyes, oils and other materials with which the treated skin may come in contact. The Company intends to continue to explore the efficacy of using its technology as a topical drug delivery system and would, when appropriate, either seek licensing arrangements with third parties, or develop and market proprietary products through its own efforts.

3

MARKETING AND DISTRIBUTION AGREEMENTS

- Home Shopping Club LP (HSN)

Effective September 1, 1999, the Company entered into a marketing and distribution agreement (the "Home Shopping Agreement") with HSN that grants HSN an exclusive worldwide license to market and distribute certain of the Company's proprietary consumer products through various forms of electronic retailing. The Home Shopping Agreement also grants HSN a non-exclusive license to market Hydron products through all other methods of distribution in certain countries outside the United States.

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

Under the terms of the Home Shopping Agreement, HSN was required to make specified product purchases during the period ending 12 months following the date on which the products first aired on HSN's television programs. Should HSN have exceeded a certain threshold amount in retail sales of Hydron products to consumers during the first twelve months, it was required to make specified product purchases during the second 12 months following the date of the first airing. The term of the Home Shopping Agreement may be automatically renewed after the Initial Term (two years after date of the first airing) for an indefinite number of successive one-year periods, subject to HSN's achieving certain escalating threshold levels in product purchases. However, beginning in the third contract year, HSN will no longer be required to meet specified product purchases, except to maintain exclusivity.

The Company launched its products on HSN's television network on September 16, 1999. Hydron products have since been featured in "Hydron Skin Care Solutions" hours during 7 of the first 12 months of the Home Shopping Agreement. While HSN has not met its purchase commitment for the first 12 months, Management is continuing to work with HSN to increase sales through their network in 2001.

In November 2000 the Company also began marketing on HSE, the Spanish language subsidiary of HSN. Hydron has secured a two-year agreement with Home Shopping Espanol (HSE), a rapidly expanding division of Home Shopping, L.P., to air Hydron products on HSE's Spanish-language television shopping programming in the United States and internationally. Hydron has retained Charytin Goyco, a well-known Latin celebrity, as Spokesperson for the Latin American Market for the same two-year period. The HSE program has already expanded beyond the US border to include Puerto Rico. Further HSE International expansion is anticipated in the first half of 2001.

In addition to selling Hydron products on-air, HSN and HSE provide brand development, and marketing promotion and support for the products, including direct mail, sampling, outbound telemarketing, package inserts, advertising and publicity programs, the costs and expenses of which are shared by the Company.

In November 1996, the Company opened a new channel of distribution for Hydron products with the launch of its proprietary Catalog. This full color Catalog offers the Company's personal care products for sale directly to consumers. The Catalog also provides information on new Hydron products, educates consumers on proper skin and hair care and facilitates re-ordering. The Company is currently exploring new ways to enhance Catalog sales and operations.

4

Although Management believes that there are other avenues for selling its products, including the Hydron catalog, the loss of HSN as a customer would have a material adverse effect on the Company's business.

- QVC, Inc.

The Company entered into a license agreement with QVC, Inc. (QVC) in 1993 ("QVC License Agreement"), whereby QVC was granted exclusive rights to market and distribute the Company's proprietary consumer products using Hydron polymers in the Western Hemisphere. In 1996, the Company and QVC modified the QVC License Agreement ("Amended License Agreement"), whereby the Company reacquired certain retail marketing rights to the Hydron product line. Effective May 31, 1999, the Company terminated the Renegotiated License Agreement as a result of QVC's failure to satisfy the annual minimum product purchase

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

requirements for the period ended May 31, 1999. The Company continues to sell certain products to QVC, on a non-exclusive basis, so that QVC can resell these products to their customers who had previously purchased the products and wish to re-order Hydron products.

Marketing and Sales

The majority of the Company's products are currently sold in the United States exclusively through direct response television and catalog sales, and on a minor level, internationally through salons and doctors offices. During the Fiscal year ended December 31, 2000 ("Fiscal 2000"), approximately half of the Company's sales were made through HSN and QVC, the world's largest electronic retailers, pursuant to the respective license agreements. See "Marketing and Distribution Agreements." The balance of sales was made through the Company's catalog operation.

- Direct Response Television

Management believes that marketing Hydron products through direct response television affords the Company several advantages over conventional in-store retailing, including: cash flow that enables the Company to finance, internally, product development and new marketing activities, the ability to take advantage of time-sensitive opportunities by moving products to market quickly, and the ability to conduct real time market research, which can allow Management to make marketing decisions quickly and cost effectively.

The Company's personal care products are presently marketed through direct response television in the United States exclusively by HSN, whose programming is transmitted live on cable television to approximately seventy million homes. Sales of the Company's products to HSN & QVC accounted for

5

approximately 50%, 68%, 79%, 82%, and 97% of the Company's total sales for Fiscal 2000, 1999, 1998, 1997, and 1996, respectively. Although Management believes that there are other avenues for selling its products, including attempting to expand its Catalog base by utilizing various marketing methods, the inability to sell through direct response television would have a material adverse effect on the Company's business.

Hydron products had been marketed on QVC through regularly scheduled hour-long programs from April 1994 through May 1999. Hydron products have been marketed through HSN through hour-long programs since September 1999. The hour-long live broadcasts generally feature most currently available products, which are sold individually or in collections (packaging of products in various combinations). The majority of Hydron products are sold in connection with on-air marketing, although customers may purchase the products outside of these hour-long programs. Such off-air or back-end sales are considered primarily re-order business.

Retail sales of Hydron products by HSN are affected primarily by the amount of hours provided, the quality of such hours (e.g., time of day or day of the week), new product introductions, competitive products offered and the effectiveness of the host and spokesperson.

In Fiscal 2000, the Company focused on re-establishing its core items on-air with HSN and launching its core line to Latin consumers through HSE. As of December 2000 the products marketed by Hydron consisted of skin care (22 sku's), hair care (7 sku's), bath and body (8 sku's) and sun care (2 sku's). Most of these products can be purchased on HSN individually or in kits or

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

collections. The Company constantly reviews its product lines and is now emphasizing the skin care line of products to a greater extent.

- Catalog Sales

In November 1996, the Company opened a new channel of distribution for Hydron products with the launch of its proprietary Catalog. This full color Catalog offers the Company's personal care products for sale directly to consumers. The Catalog also provides information on new Hydron products, educates consumers on proper skin and hair care and facilitates re-ordering. The Company is currently exploring new ways to enhance Catalog sales and operations.

The Hydron Catalog customer base was significantly expanded in Fiscal 2000 through a variety of marketing programs targeted at developing and retaining new customers. Over the past 12 months, the catalog customer base was expanded from 5,700 customers in Fiscal 1999 to over 7,500 customers in Fiscal 2000. Management is continuing to test various cost-effective direct marketing methods that can be used to acquire new customers, and enhance the purchasing frequency of the Company's current customers.

6

-Infomercial

In 1997, the Company, through its wholly-owned subsidiary, Hydron Direct, Inc., entered into an agreement with QDirect Ventures, Inc., an affiliate of QVC, Inc., to form a new joint venture, known as New Hydromercial Partners ("Infomercial Partnership"), to promote and sell the Company's Hydron polymer-based skin care products through a thirty-minute commercial ("Infomercial"), which the Infomercial Partnership produced. Although the Infomercial is not currently being aired, it had been shown on regional and national cable networks, at various times, since September 1995. The partnership has been terminated and residual equity has been distributed. Hydron has access to the partnership's 25,000 customers and is marketing direct to these customers.

- Alternative Channels of Distribution

In addition to the Company's Catalog operations, the Company intends to seek alternative channels of distribution for its products, such as private labeling, international and retail.

The Company has an agreement with an Australian-based health and beauty products distributor, Doctors Formula Pty. Ltd., to market Hydron products in retail salon stores and medical offices in Australia and New Zealand. Sales to Doctors Formula Pty. Ltd. have been minimal to date.

Agreement with National Patent

Pursuant to the terms of an agreement ("Patent Agreement") with National Patent Development Corporation ("National Patent"), the Company has the exclusive worldwide rights to market products using Hydron polymers in the oral health, personal care/cosmetic and other consumer product fields, the areas in which the Company has been concentrating its research and development efforts. The Company also has exclusive worldwide rights to utilize Hydron polymers in its topical delivery system for non-prescription drugs only. National Patent has the exclusive worldwide rights to market prescription drugs and medical devices using Hydron polymers. Furthermore, each Company has the right to exploit products with Hydron polymers not in the other's exclusive fields.

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

The Patent Agreement requires the Company to pay a 5% royalty to National Patent based on the net sales of products containing the Hydron polymer. Additionally, National Patent is required to pay the Company a 5% royalty on its net sales of Hydron polymer-based products, except with respect to certain excluded products. In the area of prescription and nonprescription drugs using Hydron polymers as a drug release mechanism, both the Company and National Patent have agreed to pay the other a royalty equal to 5% of net sales received from third parties with regard to such products developed. In addition, each will pay the other 25% of any up-front license fees, royalties or similar payments received from third parties with regard to such products developed in the area of nonprescription drugs. For the years ended December 31, 2000, 1999,

7

1998, 1997 and 1996, the Company paid or accrued royalties to National Patent of approximately \$104,000, \$130,000, \$190,000, \$330,000, and \$387,000, respectively. The Company has not received any royalties from National Patent during these periods.

Foreign Operations

Direct foreign sales by the Company have never been significant as a percentage of consolidated net sales. From 1995 to 1997, the Company marketed its products in Europe through a QVC affiliate in the United Kingdom. In 1996, the Company signed an agreement for conventional retail sales with Doctors Formula Pty. Ltd., an Australia-based health and beauty products distributor.

The Company is currently working with HSN's international subsidiary HSE to include its Spanish language show in the United States and Puerto Rico. It is anticipated HSE will eventually expand to Mexico, Latin America and South America. Management is also reviewing other opportunities to exploit its consumer products through various retail marketing and distribution methods in regions not covered under agreements with HSN.

Manufacturing and Raw Materials

Hydron polymer-based products are manufactured exclusively for the Company by independent third parties. The Company has used principally two manufacturers of cosmetic products because of the quality of their production and reasonable costs. To date, contract manufacturing has allowed the Company to meet inventory requirements in a timely manner. All raw material and packaging components for the Company's consumer and professional product lines are readily available to the Company from a variety of sources.

The Company is not dependent on any sole manufacturer except National Patent, which has agreed to make the Hydron polymer available to the Company as needed, and to provide the Company with all manufacturing procedures, including know-how, and render necessary and reasonable technical assistance should National Patent be unable to meet the Company's requirements for the Hydron polymer. The loss of National Patent as a supplier or a reduction in the availability of the Hydron polymer would have a material adverse effect on the Company's business.

Inventory

The Company did not have any backorder of firm booked orders as of December 31, 2000, and generally delivers its orders within two weeks of the date orders are booked. Although the Company's business is not seasonal, orders are placed by HSN after it determines its programming, and therefore, fluctuations in the Company's sales may occur on a monthly and quarterly basis.

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

Orders placed by the Company's Catalog customers are generally shipped within two days of the placement of the order.

8

Research and Development

Management anticipates completing development of products initiated during 2000. The Company expects to focus research and development resources on additional Hydron polymer-based products as well as other proprietary technology-based products as determined by Management's assessment of consumer demand. The Company's research and development efforts during Fiscal 2000 continued to achieve greater diversification among the Company's product lines by broadening the brand's appeal primarily to the aging baby boomer marketplace. During Fiscal 2000, the Company's contract research and development program advanced two new technologies: an adult acne line (5 products) based on proprietary delivery technology that is believed to be superior to the current market competition, and seminal research into skin anti-aging treatment, wound treatment and healing.

These efforts ultimately include product formulation, packaging design and prototypes, extensive product safety and stability testing conducted by dermatologists, along with non-comedogenicity tests where appropriate, certain efficacy studies to support product claims, and consumer focus groups and panel tests. Charles Fox, a consultant and a former member of the Company's Board of Directors from September 1997 to October 1998, leads the Company's research and development. Mr. Fox was formerly director of product development for Warner Lambert Company's personal products division and president of the Society of Cosmetic Chemists.

Patented Technology

The Company strongly believes that technology and patent protection are essential to providing a sound foundation for a new product. During 1999 the Company was granted U.S. Patent No. 5,879,684 for its Line Smoothing Complex formula. This product has been clinically shown to reduce fine lines and wrinkles. The patent has an expiration date of April 11, 2017. In addition to owning certain non-material patents relating to personal care products, the Company was granted U.S. Patent No. 4,883,659, dated November 28, 1989, and U.S. Patent No. 5,039,516, dated August 13, 1991, which cover a stable moisturizing emulsion containing an unusual emulsifying agent, as well as the Hydron polymer and a unique combination of ingredients. These patents have expiration dates of November 28, 2006 and August 13, 2008, respectively.

The Company also holds patents in numerous other countries, for its emulsification process. The Hydron Polymer, utilized in cosmetic emulsions, creates a thin moisture-attracting film that is non-greasy; is not dissolved by sebaceous oils or perspiration; does not emulsify the skin's natural oils and humectants; and allows the skin to breathe (i.e., it is air and moisture permeable). The film is insoluble in water and resistant to rub-off, but can easily be removed with cleanser and water.

In 2000, the Company discovered that the emulsion system also adjusts pH on the skin to match the pH of the stratum corneum, the skin's surface layer. It is evident in recent skin research that the pH range of Hydron is essential for contributing to the skin's natural healing process and enzyme production responsible for rebuilding the skin's lipid barrier.

9

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

The Company's Management believes that there are no competitive cosmetic products with this combination of properties. Applications for the Hydron polymer and the Company's patented technology in the cosmetics and pharmaceutical industries include more effective and prolonged delivery of moisturizing agents to the skin; enhanced flavor and scent releasing components; and a delivery system for topically applied over-the-counter medications which may enhance the penetration of active ingredients to the skin by holding them on the skin longer, in a moist environment.

Government Regulation

All of the Company's skin care, hair care, and bath and body products are "cosmetics" as that term is defined under the Federal Food, Drug and Cosmetics Act ("FDC Act"), and must comply with the labeling requirements of the FDC Act, the Fair Packaging and Labeling Act ("FPL Act"), and the regulations thereunder. Certain of the Company's products (i.e. its topical analgesic and products that contain a sunscreen or triclosan) are also classified as over-the-counter drugs. Additional regulatory requirements for such products include additional labeling requirements, registration of the manufacturer and semiannual update of the drug list. Management believes that it is in compliance with these requirements and that it faces no material costs associated with such compliance.

Competition

The skin care business is characterized by vigorous competition throughout the world. Product recognition, quality, performance and price have significant influence on customers' choices among competing products and brands. Advertising, promotion, merchandising, the pace and timing of new product introductions and line extensions also have a significant impact on the consumer buying decisions. The Company competes against a number of marketers of skin care products, some of which have substantially greater resources than the Company. Although the Company is in competition with all skin care brands, direct competition in electronic retailing and catalog sales includes Principal Secret, ProActiv, Physician's Advice, Susan Lucci, Signature Club A, Marilyn Miglin, Dr. Graff, Jennifer Flaven-Stallone's Serious Skin Care.

Seasonality

The Company's results of operations are not subject to seasonal fluctuations.

10

Employees

The Company satisfies its human resource needs utilizing an outsourcing firm that provides all administrative services relating to payroll, personnel and employee benefits. Management continues to hire, fire, set pay rates and supervise its staff. This arrangement enables the Company to reduce its administrative and benefits costs relating to employees. The Company currently has nine full time positions.

ITEM 2. PROPERTIES

The Company maintains its offices at Yamato Office Center, 1001 Yamato Road, Suite 403, Boca Raton, Florida 33431. The lease on this office space (5,500 square feet) expires in September 2001 and requires monthly rent of

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

approximately \$8,300, including taxes and common area expenses, subject to increases in the Consumer Price Index and other increases in taxes and common area expenses over set amounts. The Company subleases approximately 1,500 square feet of this office to an independent third party for \$2,800 per month, under terms similar to the Company's lease.

In August, 2000, the Company did not renew its lease for its main warehouse of approximately 31,000 square feet at 95 Mayhill Street, Saddle Brook, New Jersey 07663. The monthly rent was approximately \$14,000. The Company moved the majority of its finished goods and components to a public warehouse at 14-01 Maple Avenue, Fair Lawn, New Jersey 07410 with a monthly rent typically below \$4,000 per month.

In addition, the Company moved out of its local warehouse space, of approximately 3,200 square feet, at 1120 Holland Drive, Suites 9 and 19, Boca Raton, Florida 33487, pursuant to a lease that expired in April 2000, at a monthly rent of approximately \$2,900. This warehouse was subleased in April 1999 to an independent third party under terms similar to the original lease including the required rent and other payments. The Company no longer has any obligation under either lease.

Management believes that the current facilities are satisfactory for its present needs.

ITEM 3. LEGAL PROCEEDINGS

The Company is not a party to, and its property is not the subject of, any material pending legal proceedings.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to a vote of security holders during the quarter ended December 31, 2000.

11

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED SHAREHOLDER MATTERS

The Company's Common Stock trades on the NASDAQ Bulletin Board Market tier of the NASDAQ Stock Market (the "NASDAQ BB Market") under the symbol HTEC. The following tables indicate the high and low closing prices for the Company's Common Stock (restated for the one-for-five reverse stock split effective October 19, 1998), as reported by the NASDAQ Stock Market.

Fiscal 2000 -----	High Closing Price -----	Low Closing Price -----
Fourth Quarter	\$.281	\$.125
Third Quarter	.406	.125
Second Quarter	.469	.188
First Quarter	.625	.375

Fiscal 1999 -----	High Closing Price -----	Low Closing Price -----
Fourth Quarter	\$.844	\$.437
Third Quarter	.906	.562
Second Quarter	1.250	.500
First Quarter	1.062	.500

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

As of March 28, 2001, there were approximately 3,952 record holders of the Company's Common Stock. The Board of Directors will determine the payment of dividends in the future in light of conditions then existing, including the Company's earnings and financial condition.

ITEM 6. SELECTED FINANCIAL DATA

	Fiscal Years Ended December 31,			
	2000	1999	1998	1997
Net Sales	\$ 2,081,568	\$ 2,593,448	\$ 3,983,303	\$ 7,305,154
Distribution Agreement Expense	--	--	--	--
Operating Income (Loss)	(946,771)	(3,064,189)	(2,067,349)	(2,849,790)
Interest and Investment Income	20,945	80,860	144,203	211,371
Net Income (Loss)	(923,632)	(2,974,142)	(1,882,667)	(2,588,492)
Basic & Diluted Earnings				
(Loss) per Common Share	(.19)	(.60)	(.38)	(.54)
Total Assets	2,800,515	3,835,303	6,641,433	8,751,343
Total Shareholders' Equity	2,141,640	3,065,272	5,974,571	7,857,238

12

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

The Company sells specialty personal care/cosmetics products, primarily for skin care, and to a lesser extent oral health care products, most of which are covered by patent, license and/or royalty agreements. The Home Shopping Agreement provides HSN with certain exclusive rights to purchase certain products solely from the Company for sale in direct response television and other distribution channels. In addition, the Patent Agreement with National Patent provides for reciprocal royalty payments based on the sale of certain of each party's products. The Company is developing other personal care/cosmetics for consumers using Hydron polymers and other technology. The Company also has a patented technology in which the Hydron polymers act as a drug release mechanism and the Company intends to continue to explore the efficacy of using this technology to either seek licensing arrangements with third parties, or develop and market proprietary products through its own efforts.

Results of Operations - Fiscal 2000 versus Fiscal 1999

Net sales for Fiscal 2000 were \$2,081,468, a decrease of \$511,980, or 20%, from net sales of \$2,593,448 for the Fiscal year ended December 31, 1999 ("Fiscal 1999"). During Fiscal 2000, catalog sales increased by approximately \$209,369, or 25%, from \$827,226 in Fiscal 1999 to \$1,036,595 in Fiscal 2000. The increase in Catalog sales resulted primarily from a substantial increase in the new customer trial and consistent promotional pressure against existing customers. The customer base for the Company was increased by 32% during the year as trial events on the Web and through direct mail events brought in new customers.

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

Non-catalog sales, including all sales to HSN and QVC, decreased by approximately \$721,350, or 41%, from \$1,766,223 in Fiscal 1999 to \$1,044,873 in Fiscal 2000. HSN sales slowed as the show schedule decreased on the HSN domestic channel, offset by an increase as HSE geared up for the Latin market introduction in November.

Approximately 63% of the Company's non-catalog sales during Fiscal 2000 were to HSN and approximately 36% of non-catalog sales were to QVC. Management anticipates that sales to HSN will grow to be a larger percentage of the Company's sales and, absent the consummation of marketing or distribution arrangements with third parties other than HSN, the Company's dependence upon direct response television as a distribution channel will decrease but remain significant. Any disruption in the Company's relationship with HSN would have a material adverse effect on the business, financial condition and results of operations of the Company.

As a result of several positive factors, the Company's overall gross profit margin increased to 78% of net sales for Fiscal 2000 versus 22% for Fiscal 1999. Factors improving the margin include: 1) a significant increase in high margin catalog sales which maintained gross profit margin of 83% in 2000

13

from 84% in 1999, 2) an improvement in the product mix (fewer introductory kits) sold to electronic retailers, improving margins to 61% in 2000 from 59% in 1999; and 3) a one-time reversal of reserves for a packaging contract that was favorably renegotiated, representing \$175,000 or 11% of gross sales in Fiscal 2000. Further exacerbating the annual gross margin comparison of 2000 to 1999, the Company reflected an inventory write-down of \$794,362 in 1999 that represented 31% of net sales for 1999. There was no corresponding write-down of inventory for 2000. The write-down to net realizable value represents components and finished goods of product that the Company deemed were in excess based on current sales levels or does not plan to continue marketing in the future.

Substantially all of the inventory components and finished goods written down resulted from the conversion to HSN from QVC as the primary channel of distribution, or were purchased and/or manufactured prior to September 1997. The write-down applies primarily to components and finished goods outside of the traditional skin care product line, such as hair care, sun care, and bath and body products. The Company will make every effort to recoup as much value as possible as it examines various means of liquidating the current excess. Of the excess, approximately \$73,000 of the inventory has been sold.

Royalty expenses in Fiscal 2000 were \$103,558, representing a decrease of \$38,416, or 27%, from royalty expenses of \$141,974 in Fiscal 1999. Royalties for Fiscal 1999 included royalties due under the QVC agreement. The decrease in Fiscal 2000 is commensurate with the decrease in gross sales for the Company in Fiscal 2000 when QVC royalties are excluded. These expenses are related primarily to the Patent Agreement with National Patent and pertain to the use of the Hydron polymers as a formula ingredient for many of the Company's products.

Research and Development ("R&D") expenses reflect the Company's efforts to identify new product opportunities, develop and package the products for commercial sale, perform appropriate efficacy and safety tests, and conduct consumer panel studies and focus groups. R&D expenses in Fiscal 2000 were \$84,108, a decrease of \$127,848, or 60%, from R&D expenses of \$211,956 in Fiscal 1999. In changing to a new electronic retailer, the Company's first priority was to establish the core line with the new TV audience. The need for new product introduction is more important for the second year and beyond. The amount of R&D expenses per year varies, depending on the nature of the development work during

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

each year, as well as the number and type of products under development at such time.

Selling, general and administrative ("SG&A") expenses in Fiscal 2000 were \$1,926,959, representing a decrease of \$233,268, or 11%, from SG&A expenses of \$2,160,227 in Fiscal 1999. This decrease is the result of: 1) lower marketing and promotional expenses (\$123,000), 2) reduced expenses related to outside consultants (\$103,000), 3) reduced expenses for warehouse rent since September (\$56,000), and 4) reduced insurance premiums (\$47,000). These cost reductions were partially offset by 1) increased catalog postage and handling associated with attracting new customers (\$44,000), and 2) increased MIS expenses required for catalog sales growth, including Hydron Website redesign (\$41,000).

14

There were no employment contract settlement costs in Fiscal 2000, a 100% decrease from employment contract settlement costs of \$620,099 for Fiscal 1999. These costs related to the settlement terms and associated legal fees regarding several employment contracts. These contracts, which originated during Fiscal 1993 and Fiscal 1994, overburdened the Company's operations during a period when the Company's revenues could not support the contracts. The Company does not currently have any employment contracts.

Interest and investment income in Fiscal 2000 was \$20,945, a decrease of \$59,915, or 74%, from interest income of \$80,860 in Fiscal 1999, due primarily to lower cash balances resulting from the factors discussed above. The Company maintains a conservative investment strategy, deriving investment income primarily from U.S. Treasury securities.

The Company had a net loss for Fiscal 2000 of \$923,632, a reduced loss of \$2,050,510, or 69% from the net loss of \$2,974,142 for Fiscal 1999, primarily as a result of the factors discussed above.

Results of Operations - Fiscal 1999 versus Fiscal 1998

Net sales for Fiscal 1999 were \$2,593,448, a decrease of \$1,389,855, or 35%, from net sales of \$3,983,303 for the Fiscal year ended December 31, 1998 ("Fiscal 1998"). During Fiscal 1999, catalog sales increased by approximately \$58,000, or 8%, from \$769,000 in Fiscal 1998 to \$827,000 in Fiscal 1999. The increase in Catalog sales resulted primarily from an increase in the number of new customers and a major "25% off" sale in the summer. Non-catalog sales, including all sales to QVC and HSN, decreased by approximately \$1,448,000, or 45%, from \$3,214,000 in Fiscal 1998 to \$1,766,000 in Fiscal 1999. QVC sales slowed as the May 31, 1999 contract anniversary date approached and the contract required the Company to refrain from selling its products on any form of direct response television prior to September 1, 1999.

Approximately 63% of the Company's non-catalog sales during Fiscal 1999 were to QVC and approximately 37% of non-catalog sales were to HSN. Management anticipates that sales to HSN will grow to be a larger percentage of the Company's sales and, absent the consummation of marketing or distribution arrangements with third parties other than HSN, the Company's dependence upon direct response television as a distribution channel will remain significant. Any disruption in the Company's relationship with HSN would have a material adverse effect on the business, financial condition and results of operations of the Company.

As a result of an inventory write-down, the Company's overall gross profit margin decreased to 22% of net sales for Fiscal 1999 from 49% for Fiscal 1998. The Company took an inventory write-down of \$794,362 and \$442,254 in

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

Fiscal 1999 and Fiscal 1998, respectively. The write-downs to net realizable

15

value represent components and finished goods of product that the Company deems are in excess based on current sales levels or does not plan to continue marketing in the future. The gross margin on catalog sales, excluding the write-down of inventory, increased to 84% of net sales in Fiscal 1999 from 79% in Fiscal 1998. The gross margin on non-catalog sales, excluding the write-down of inventory, grew to 59% for Fiscal 1999, up from 56% of net sales for Fiscal 1998. The increases in gross margins are attributable to a shift in the mix of product sold to more profitable items.

Substantially all of the inventory components and finished goods written down resulted from the conversion to HSN from QVC as the primary channel of distribution, or were purchased and/or manufactured prior to September 1997. The write-down applies primarily to components and finished goods outside of the traditional skin care product line, such as hair care, sun care, and bath and body products. The Company will make every effort to recoup as much value as possible as it examines various means of liquidating the current excess.

Royalty expenses in Fiscal 1999 were \$141,974, representing a decrease of \$72,440, or 34%, from royalty expenses of \$214,414 in Fiscal 1998. This decrease is commensurate with the decrease in gross sales for the Company in Fiscal 1999. These expenses are related primarily to the Patent Agreement with National Patent and pertain to the use of the Hydron polymers as a formula ingredient for many of the Company's products.

Research and development ("R&D") expenses reflect the Company's efforts to identify new product opportunities, develop and package the products for commercial sale, perform appropriate efficacy and safety tests, and conduct consumer panel studies and focus groups. R&D expenses in Fiscal 1999 were \$211,956, a decrease of \$138,873, or 40%, from R&D expenses of \$350,829 in Fiscal 1998. The amount of R&D expenses per year varies, depending on the nature of the development work during each year, as well as the number and type of products under development at such time.

Selling, general and administrative ("SG&A") expenses in Fiscal 1999 were \$2,160,227, representing a decrease of \$151,052, or 7%, from SG&A expenses of \$2,311,279 in Fiscal 1998. This decrease is primarily the result of lower executive salary expense. Expenses attributed to the Catalog include advertising, additional marketing, customer service and warehouse personnel, and related telephone, postage and supply expenses. Advertising was the most significant Catalog expense, totaling approximately \$109,000 in Fiscal 1999 and approximately \$119,000 in Fiscal 1998.

Employment contract settlement costs in Fiscal 1999 were \$620,099, a decrease of \$7,614, or 1%, from employment contract settlement costs of \$627,713 for Fiscal 1998. These costs related to the settlement terms and associated legal fees regarding several employment contracts. These contracts, which originated during Fiscal 1993 and Fiscal 1994, overburdened the Company's operations during a period when the Company's revenues could not support the contracts. The Company does not currently have any employment contracts.

16

Interest and investment income in Fiscal 1999 was \$80,860, a decrease of \$63,343, or 44%, from interest income of \$144,203 in Fiscal 1998, due

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

primarily to lower cash balances resulting from the factors discussed above. The Company maintains a conservative investment strategy, deriving investment income primarily from U.S. Treasury securities.

The Company had a net loss for Fiscal 1999 of \$2,974,142, an increase of \$1,091,475, or 58% from the net loss of \$1,882,667 for Fiscal 1998, primarily as a result of the factors discussed above. Excluding the write-down of inventory and the employment contract settlement costs, the net loss for Fiscal 1999 and Fiscal 1998 would have been \$1,559,681 and \$812,700, respectively.

Results of Operations - Fiscal 1998 versus Fiscal 1997

Net sales for Fiscal 1998 were \$3,983,303, a decrease of \$3,321,851, or 45%, from net sales of \$7,305,154 for the Fiscal year ended December 31, 1997 ("Fiscal 1997"). During Fiscal 1998, catalog sales decreased by approximately \$532,000, or 41%, from \$1,301,000 in Fiscal 1997 to \$769,000 in Fiscal 1998. The decrease in Catalog sales resulted primarily from decreased promotion of the catalog. Although catalog sales decreased, the catalog was profitable in Fiscal 1998 as compared to a loss of approximately \$1.9 million in Fiscal 1997. Non-catalog sales, including sales to QVC and its affiliates, decreased by approximately \$2,790,000, or 46%, from \$6,004,000 in Fiscal 1997 to \$3,214,000 in Fiscal 1998. The decrease in non-catalog sales resulted primarily from decreased sales to QVC, which in turn, resulted primarily from a reduction in QVC's retail sales due to the amount and quality of hours provided by QVC, as well as the number of new product introductions, the amount of competitive products offered by QVC and the effectiveness of the host and spokesperson.

Approximately 79% and 82% of the Company's non-catalog sales during Fiscal 1998 and Fiscal 1997, respectively, were to QVC and its related entities, including the Infomercial partnership and QVC Europe. Sales to QVC will continue to be a large percentage of the Company's sales and, absent the consummation of marketing or distribution arrangements with third parties other than QVC, the Company's dependence upon QVC as a substantial customer will remain significant. Any disruption in the Company's relationship with QVC would have a material adverse effect on the business, financial condition and results of operations of the Company.

The Company's overall gross profit margin decreased to 49% of net sales for Fiscal 1998 from 51% for Fiscal 1997. The gross margin on non-catalog sales, excluding the write-down of inventory, including sales to QVC and affiliates, remained at 56% of net sales for both Fiscal 1998 and Fiscal 1997. The decrease in overall gross profit margin relates primarily to the write-down, to net realizable value, of components and finished goods of products that the Company did not plan to continue marketing in the future. Substantially all of these

17

components and finished goods were purchased and/or manufactured prior to September 1997. Management decided that there was no viable market for these products, which consisted mainly of products outside of the traditional skin care product line, such as hair care, sun care and bath and body products. Disposal of inventory of \$651,270 in Fiscal 1997 related primarily to the write-down, to net realizable value, of the Company's vitamin and nutritional supplement line of products. The Company has discontinued this line of products. The gross margin on catalog sales, excluding the write-down of inventory, decreased to 79% of net sales in Fiscal 1998 from 80% in Fiscal 1997.

Royalty expenses in Fiscal 1998 were \$214,414, representing a decrease of \$172,293, or 45%, from royalty expenses of \$386,707 in Fiscal 1997. This decrease is commensurate with the decrease in gross sales for the Company in

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

Fiscal 1998. These expenses are related primarily to the Patent Agreement with National Patent and pertain to the use of the Hydron polymers as a formula ingredient for many of the Company's products.

R&D expenses reflect the Company's efforts to identify new product opportunities, develop and package the products for commercial sale, perform appropriate efficacy and safety tests, and conduct consumer panel studies and focus groups. R&D expenses in Fiscal 1998 were \$350,829, an increase of \$45,919, or 15%, from R&D expenses of \$304,910 in Fiscal 1997. The amount of R&D expenses per year varies, depending on the nature of the development work during each year, as well as the number and type of products under development at such time.

SG&A expenses in Fiscal 1998 were \$2,311,279, representing a decrease of \$3,031,350, or 57%, from SG&A expenses of \$5,342,629 in Fiscal 1997. This decrease is the result primarily of lower expenses associated with the Hydron Catalog. Total Catalog SG&A expenses in Fiscal 1998 were approximately \$426,000, a decrease of approximately \$1,874,000, or 81%, from Catalog SG&A expenses of approximately \$2,300,000 in Fiscal 1997. Expenses attributed to the Catalog include advertising, additional marketing, customer service and warehouse personnel, and related telephone, postage and supply expenses. Advertising was the most significant Catalog expense, totaling approximately \$119,000 in Fiscal 1998 and approximately \$1.6 million in Fiscal 1997. Included in advertising in Fiscal 1997 were sports sponsorship expenses of approximately \$771,000. Such sports sponsorships were discontinued during Fiscal 1997.

SG&A expenses, other than Catalog related expenses, in Fiscal 1998 were approximately \$1,885,000, a decrease of approximately \$1,158,000, or 38%, from such expenses of approximately \$3,131,000 in Fiscal 1997. This decrease was due primarily to a reduction in legal expenses. In 1997 legal expenses included approximately \$470,000 incurred in connection with the dispute between the Company and certain shareholders of the Company (including certain current directors of the Company) who were members of a group ("13D Group") through September 19, 1997, including the legal fees and expenses of the 13D Group reimbursed by the Company.

18

Employment contract settlement costs in Fiscal 1998 were \$627,713, an increase of \$552,984, or 640%, from employment contract settlement costs of \$74,729 for Fiscal 1997. This increase pertained primarily to legal fees and related expenses in connection with the litigation with Harvey Tauman, and approximately \$391,000 in payroll and related expenses relating to the voluntary early termination of another executive officer's employment contract that would have otherwise provided for continued employment through August 31, 2004. The contract is now settled.

Interest and investment income in Fiscal 1998 was \$144,203, a decrease of \$67,168, or 32%, from interest income of \$211,371 in Fiscal 1997, due primarily to lower cash balances as a result of the factors discussed above. The Company maintains a conservative investment strategy, deriving investment income primarily from U.S. Treasury securities.

The Company had a net loss for Fiscal 1998 of \$1,882,667, a decrease of \$705,825, or 27%, from the net loss of \$2,588,492 for Fiscal 1997, primarily as a result of the factors discussed above. Excluding the write-down of inventory and the employment contract settlement costs, the net loss for Fiscal 1998 and Fiscal 1997 would have been \$812,700 and \$1,862,493, respectively.

Liquidity and Capital Resources

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

The Company's working capital was approximately \$ 1,197,392 at December 31, 2000, including cash and cash equivalents of approximately \$190,946. Cash used for operations was \$527,885. This was offset by Investing Activities (\$64,915) that provided cash from the liquidation of the joint venture. There were no Financing Activities.

The Company has incurred significant losses over the past five years. The ability of the Company to continue as a going concern is dependent on increasing sales while managing operating expenses.

Management's plan to increase sales and reduce operating expenses includes several specific actions. Catalog sales will continue to be emphasized since they have higher profit margins and represent markets for the Company that are growing more rapidly than the Company's traditional television market. Direct marketing techniques will be used to reach new and current consumers such as promotions mailed to targeted consumers, Web site specials, promotions to other Web site customers, and direct e-mail promotions to new customers. Additional revenue streams will be added through international distribution.

The Company will make every effort to expand its television sales presence with HSN and HSE. The Company is negotiating with HSN to set a schedule of show hours that will allow for the organized development of new products appropriate to the venue.

19

In addition, the Company has added a significant private label customer utilizing Hydron polymer based formulas. Initial orders are expected in the second quarter, 2001.

The Company is also pursuing international distribution agreements that will expand the Company's distribution around the world. Regarding new products and markets, the Company will continue to develop proprietary technology that it believes will improve its long-term success in the category.

Based on the above plan and the Company's present cash position, the absence of any short or long term debt, arrangements with third parties for contractual manufacturing and R&D, and the Company's present business strategy, Management believes that the Company has adequate resources to meet normal, recurring obligations, for at least the next twelve months, as they become due. Further, in view of the payment terms in connection with sales to HSN, Management does not anticipate any difficulty in financing foreseeable inventory requirements.

The Company does not have the financial resources to sustain a national advertising campaign to market its products in a conventional retail mode. In view of the foregoing, Management's strategy has been to enter into marketing, licensing and distribution agreements with third parties (such as HSN, QVC and the Infomercial Partnership) which have greater financial resources than those of the Company and that can enhance the Company's product introductions with appropriate national marketing support programs.

The effect of inflation has not been significant upon either the operations or financial condition of the Company.

Cautionary Statement Regarding Forward Looking Statements

The statements contained in this Report on Form 10-K that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

of 1934, including statements regarding the Company's expectations, hopes, intentions, beliefs or strategies regarding the future. Forward looking statements include the Company's liquidity, anticipated cash needs and availability, and the anticipated expense levels under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations." All forward looking statements included in this document are based on information available to the Company on the date of this Report, and the Company assumes no obligation to update any such forward looking statement. It is important to note that the Company's actual results could differ materially from those expressed or implied in such forward looking statements.

20

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

The information required by this item is set forth in the Consolidated Financial Statements contained in this report and is incorporated herein by reference.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The Consolidated Financial Statements of the Company are contained in this report following Item 14.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

21

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

Identification of Directors and Executive Officers

Listed below are the directors and executive officers of the Company as of December 31, 2000:

Name	Position
Richard Banakus	Director, Chairman of the Board and Interim President
Joshua Rochlin	Director
Karen Gray	Director
Charles Johnston	Director
Terrence McGrath	Chief Operating Officer
William Fagot	Chief Financial Officer

Business Experience

Richard Banakus, age 54, has served as a director of the Company since June 1995 and as Interim President of the Company since September 19, 1997. From April 1991 to the present, Mr. Banakus has been a private investor with interests in a number of privately and publicly held companies. From July 1988 through March 1991, he was managing partner of Banyan Securities, Larkspur, California, a securities brokerage firm that he founded.

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

Joshua Rochlin, age 34, has served as director for the Company since January 2000. Mr. Rochlin joined GoAmerica, a wireless Internet service provider, in December 1999. He is currently Vice President of Business Development at GoAmerica. Prior to joining GoAmerica, Mr. Rochlin was the founder and Chief Executive Officer of MyCalendar.com, LLC from January 1999 to December 1999. He previously served as an associate for the law firm of Rubin Baum Levin Constant & Friedman in New York City from February 1995 to December 1998.

Karen Gray, age 42, has served as a director of the Company since December 1997 and has been a consultant to the Company on marketing and communications matters since November 1996. Ms. Gray has over 16 years of management experience in marketing communications in various capacities with various companies. From 1993 to November 1996, Ms. Gray served as Vice President, Corporate Communications, of the Company. From June 1992 to November 1993, Ms. Gray served as President of MarCom Associates, Inc., a marketing communications company that she founded.

Charles Johnston, age 65, has served as a director of the Company since December 1997. During the past 11 years he has served on various boards. Mr. Johnston is currently Chairman of Ventex Technology, Inc. an electronic transformer company in Riviera Beach, Florida and AFD Technologies, LLC a chemical company in Richmond, VA. He was previously founder, Chairman and CEO of

22

ISI Systems, a computer software company listed on the American Stock Exchange prior to its sale in November 1989 to Teleglobe Corporation in Montreal, Canada. Mr. Johnston also serves as a Trustee of Worcester Polytechnic Institute in Worcester, MA and of the Psychiatric Research Center at the University of Pennsylvania. In addition, he serves as a director of the following companies: Internet Commerce Corporation, an internet company in New York City; Bitwise Designs, Inc., Schenectady, NY and McData Corporation, Bloomfield, CO.

Terrence McGrath, age 43, has served as Chief Operating Officer of the Company since January 2000. Mr. McGrath has 23 years marketing, brand management and sales experience in a diverse range of consumer goods and cosmetic categories including Procter & Gamble Toiletries Division, Noxell, Makers of Cover Girl and Noxzema products where he specialized in new category product development; The Isaly Klondike Company where he served as VP Marketing for Klondike Ice Cream; and Pioneer Products, where he served as VP Marketing and Sales for Betty Crocker licensed products.

William Fagot, age 57, has served as Chief Financial Officer of the Company since March 2000. Mr. Fagot has 20+ years experience in companies that manufacture and market consumer products including The Seven-Up Company and Isaly Klondike Company. He held the position of Chief Financial Officer for these companies as well as a pension & welfare organization. He is a CPA, obtaining his experience with Ernst & Young.

Compliance with Section 16(A) of the Securities Exchange Act of 1934

The Company's officers, directors and beneficial owners of more than 10% of any class of its equity securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 ("Reporting Persons") are required under the Act to file reports of ownership and changes in beneficial ownership of the Company's equity securities with the Securities and Exchange Commission. Copies of those reports must also be furnished to the Company. Based solely on a review of the copies of reports furnished to the Company pursuant to the Act, the Company believes that during the fiscal year ended December 31, 2000, all filing

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

requirements applicable to Reporting Persons were complied with, except with respect to Mr. Richard Banakus, Mr. Joshua Rochlin, Ms. Karen Gray, and Mr. Charles Johnston, Directors of the Company, for whom there was one late filing each on Form 4 for the month of May (the grant of options).

ITEM 11. EXECUTIVE COMPENSATION

The following table sets forth information for the years ended December 31, 2000, 1999 and 1998 with respect to all compensation awarded to, earned by, or paid to the Company's Chief Executive Officer and Chief Operating Officer. None of the Company's other executive officers received salary and bonus payments in excess of \$100,000 during the year ended December 31, 2000.

23

SUMMARY COMPENSATION TABLE ANNUAL COMPENSATION

NAME AND PRINCIPLE POSITION	YEAR	SALARY	BONUS	OTHER ANNUAL COMPENSATION
Richard Banakus, Interim President & CEO	2000	\$ 20,000	0	
	1999	\$ 55,771	0	
	1998	\$ 120,016	0	
Terrence S. McGrath, COO	2000	\$ 110,800	0	

During Fiscal 2000, the members of the Board were granted options to purchase 2,000 shares of the Company's common stock for participation on the Company's Board of Directors.

The following table sets forth certain information relating to option exercises effected during the year ended December 31, 2000, and the value of options held as of such date by the Company's Chief Executive Officer and all other persons who were executive officers of the Company and its subsidiaries for the year ended December 31, 2000. The Company does not have any outstanding stock appreciation rights.

AGGREGATE OPTION EXERCISES FOR THE YEAR ENDED DECEMBER 31, 2000 AND YEAR END OPTION VALUES

Name	Shares Acquired On Exercise	Value (\$) Realized(2)	Number of Securities underlying unexercised options at December 31, 2000 Exercisable/ Unexercisable	Value(1) of unexe in-the-money op at December 31, exercisable unexercisab
Richard Banakus	-0-	-0-	110,000/19,500	-0-/-0-

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

Employment Agreement

On September 19, 1997, the Board of Directors appointed Richard Banakus to serve as President of the Company on an interim basis. The Board agreed to pay Mr. Banakus a monthly salary of \$10,000 and to reimburse his lodging expenses in Boca Raton, Florida and travel expenses to and from California,

(1) Total value of unexercised options is based upon the closing price (\$.1250) of the Common Stock as reported by NASDAQ on December 31, 1999.

(2) Value realized in dollars is the amount that the shareholder is deemed to have received as the result of the exercise of options, based upon the difference between the fair market value of the Common Stock as reported by NASDAQ on the date of exercise price of the options.

24

where Mr. Banakus resides. During April 1999, Mr. Banakus' salary was reduced to \$5,000 per month. During May 1999, the Company granted Mr. Banakus options to purchase 100,000 shares of the Company's common stock at an exercise price of \$0.8125 per share in exchange for a further salary reduction to \$1,666 per month through the remainder of 1999 and into 2000.

Compensation of Directors

Employees of the Company who also serve as directors are not entitled to any additional compensation for such service, except for Mr. Richard Banakus, Chairman of the Board, because of his status as Interim President. The Company does not have a written employment agreement with Mr. Banakus.

Nonemployee directors receive an annual fee of \$5,000, paid quarterly. During Fiscal 2000, each of Messrs. Richard Banakus, Karen Gray and Charles Johnston were paid \$5,000 for their service as a director; Mark Egide was paid \$1,250 for his service as a director; and Joshua Rochlin was paid \$3,750 for his services as a director.

The 1993 Nonemployee Director Stock Option Plan ("1993 Plan") was adopted by the Board of Directors on December 22, 1993, approved by the shareholders on July 19, 1994 and approved, as amended, by the shareholders on December 17, 1997. The purpose of the 1993 Plan is to assist the Company in attracting and retaining key directors who are responsible for continuing the growth and success of the Company. No options were granted under the 1993 Plan during the year ended December 31, 2000.

On November 10, 1997, the Board of Directors of the Company adopted the 1997 Nonemployee Stock Option Plan ("1997 Plan"). This plan was approved by the shareholders on December 17, 1997. The purpose of the 1997 Plan is to assist the Company in attracting and retaining experienced and knowledgeable nonemployee directors who will continue to work for the best interests of the Company.

The 1997 Plan provides nonqualified stock options for nonemployee directors to purchase an aggregate of 100,000 shares of Common Stock, with grants of options to purchase 2,000 shares to each nonemployee director on October 1, 1997, grants of options to purchase 2,000 shares on each May 1st thereafter (starting in 1999), and grants of options to purchase 2,000 shares upon election or appointment of any new nonemployee directors. The options are not exercisable for a one-year period and are to be granted at an exercise price equal to the average fair market value of the Common Stock during the ten business days preceding the day of the grant of the option. Under the provisions

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

of the 1997 Plan, Karen Gray and Charles Johnson were granted options to purchase 2,000 shares of the Company's common stock at an exercise price of \$.37034 on May 1, 2000. As a new Board member, Joshua Rochlin was granted an option to purchase 2,000 shares of the Company's common stock at an exercise price of \$.49842 on January 6, 2000.

25

The 1997 Plan also provides nonqualified stock options for nonemployee directors who serve on committees of the Board of Directors. The options are not exercisable for a one year period and are to be granted at an exercise price equal to the average fair market value of the Common Stock during the ten business days preceding the day of the grant of the option. No options were granted under this provision of the 1997 Plan during the year ended December 31, 2000.

During August 1999, the Company agreed to grant an option to purchase 18,000 shares of the Company's common stock to each of the five individuals comprising the Board of Directors, subject to shareholders' approval at the next annual meeting at an exercise price of \$.64065 per share. Since the options have been granted pending shareholders' approval, the options are reflected as outstanding as of December 31, 2000.

26

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information as of December 31, 2000 regarding (i) the share ownership of the Company by each person who is known to the Company to be the record or beneficial owner of more than five percent (5%) of the Common Stock, (ii) the share ownership of each director of the Company, (iii) the Chief Executive Officer of the Company and each other most highly paid executive officer of the Company who earned in excess of \$100,000 during the year ended December 31, 2000, and (iv) the share ownership of the Company of all directors and executive officers of the Company, as a group (six persons).

Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership	Approximate Percent of Class
Richard Banakus 82 Verssimo Drive Novato, CA 94947	450,000 (3)	8.8%
Karen Gray P.O. Box 478 Cutchogue, NY 11935	11,000 (4)	Less than 1%
Charles Johnston 706 Ocean Drive Juno Beach, FL 33408	86,500 (5)	1.7%
Joshua Rochlin 1365 Milford Terrace Teaneck, NJ 07666	2,000 (6)	Less than 1%
All directors and executive officers as a group (6 persons)	551,500 (7)	10.7%

(3) Consists of 340,000 shares held directly and 110,000 shares issuable upon

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

exercise of options. Does not include 19,500 shares of Common Stock underlying options not currently exercisable.

(4) Consists of 3,000 shares held directly and 8,000 shares issuable upon exercise of options. Does not include 20,000 shares of Common Stock underlying options not currently exercisable.

(5) Consists of 80,000 shares held directly and 6,500 shares issuable upon exercise of options. Does not include 20,000 shares of Common Stock underlying options not currently exercisable.

(6) Consists of 2,000 shares issuable upon exercise of options. Does not include 2,000 shares of Common Stock underlying options not currently exercisable.

(7) Consists of 423,000 shares held directly and 128,500 shares issuable upon exercise of options. Does not include 61,500 shares of Common Stock underlying options not currently exercisable.

27

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

The Company has paid a consultant, who was a director from September 1997 to October 1998, advisory fees and expense reimbursements of approximately \$63,000 during the year ended December 31, 2000.

28

PART IV

ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K

(a) (1) Financial Statements

The following financial statements required by Item 8 follow Item 14 of this Report:

	Page
Reports of Independent Certified Public Accountants	34-35
Financial Statements:	
Consolidated Balance Sheets, December 31, 2000 and 1999	36
Consolidated Statements of Operations for the Years ended December 31, 2000, 1999 and 1998	37
Consolidated Statements of Shareholders' Equity for the Years ended December 31, 2000, 1999 and 1998	38
Consolidated Statements of Cash Flows for the Years ended December 31, 2000, 1999 and 1998	39
Notes to Consolidated Financial Statements	40-54

All financial schedules are omitted since the required information is not

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

present, is not in significant amounts sufficient to require submission of the schedules or because the information required is included in the Consolidated Financial Statements or notes thereto.

(a) (3) Exhibits

3.1 Restated Certificate of Incorporation of Dento-Med Industries, Inc. ("Dento-Med"), as filed with the Secretary of State of New York on March 4, 1981. (8)

3.2 By-laws of the Company, as amended March 17, 1988. (9)

(8) Incorporated by reference to the Company's report on Form 10-K for the year ended December 31, 1985.

(9) Incorporated by reference to the Company's report on Form 10-K for the year ended December 31, 1987.

29

3.3 Certificate of Amendment of the Restated Certificate of Incorporation of Dento-Med, as filed with the Secretary of State of New York on November 14, 1988 (filed as Exhibit 3.2 therein). (10)

3.4 Certificate of Amendment of the Restated Certificate of Incorporation of Dento-Med, as filed with the Secretary of State of New York on July 30, 1993. (11)

4.0 Non-Qualified Stock Option Plan. (12)

4.1 Incentive Stock Option Plan, as amended January 2, 1987. (9)

4.2 1989 Stock Option Plan (3)

4.10 1993 Nonemployee Director Stock Option Plan. (11)

4.11 Warrant Purchase Agreement dated as of May 31, 1996 between QVC and the Company, filed as Exhibit 4.1 therein. (14)

10.6 Indemnification Agreement dated September 23, 1988 between Dento-Med and Harvey Tauman (filed therein as Exhibit 10.8). (10)

10.8 Indemnification Agreement dated September 23, 1988 between Dento-Med and Frank Fiur (filed therein as Exhibit 10.10). (10)

10.9 Indemnification Agreement dated September 23, 1988 between Dento-Med and Chaudhury M. Prasad (filed therein as Exhibit 10.11). (10)

10.10 Agreement between Dento-Med and National Patent dated November 30, 1989. (15)

10.11 Indemnification Agreement dated May 9, 1989 between Dento-Med and Samuel M. Leb, M.D. (13)

10.12 Indemnification Agreement dated May 9, 1989 between Dento-Med and Richard Tauman. (13)

10.13 Indemnification Agreement dated January 14, 1992 between Dento-Med and Joseph A. Caccamo, Attorney at Law, P.C. (16)

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

(10) Incorporated by reference to the Company's report on Form 10-K for the year ended December 31, 1988.

(11) Incorporated by reference to the Company's report on Form 10-K for the year ended December 31, 1993.

(12) Incorporated by reference to the Company's report on Form 10-K for the year ended December 31, 1986.

(13) Incorporated by reference to the Company's report on Form 10-K for the year ended December 31, 1989.

(14) Incorporated by reference to the Company's report on Form 8-K (date of event - July 19, 1996).

(15) Incorporated by reference to the Company's report on Form 8-K (date of event - November 30, 1989).

(16) Incorporated by reference to the Company's report on Form 10-K for the year ended December 31, 1991.

30

10.23 License Agreement dated December 6, 1993 between QVC Network, Inc. and the Company (filed in excised form, as confidential treatment has been granted for certain portions thereof). (17)

10.24 Amended and Restated Employment Agreement between Dento-Med and Harvey Tauman dated May 13, 1993. (11)

10.25 Amendment to Amended and Restated Employment Agreement between Dento-Med and Harvey Tauman dated December 20, 1993. (11)

10.26 Amended and Restated Employment Agreement between Dento-Med and Chaudhury M. Prasad dated May 13, 1993. (11)

10.27 Indemnification Agreement dated April 22, 1993 between the Company and Nestor Cardero. (11)

10.28 Indemnification Agreement dated April 22, 1993 between the Company and Karen Gray. (11)

10.31 Letter Agreement among QDirect, Inc., Hydron Direct, Inc. and DTR Associates dated January 17, 1995. (18)

10.35 Employment Agreement dated September 16, 1994 between the Company and Richard Tauman. (19)

10.36 Letter Agreement dated December 22, 1994 among the Company, Roy Reiner and Chemaïd Laboratories, Inc. (19)

10.37 Indemnification Agreement dated February 21, 1995 between the Company and Thomas G. Burns. (19)

10.38 Lease for 1001 Yamato Road, Suite 403, Boca Raton, Florida between PFRS Yamato Corp. and the Company dated May 8, 1995. (20)

10.39 First Amendment to Lease for 1001 Yamato Road, Suite 403, Boca Raton, Florida between PFRS Yamato Corp. and the Company dated September 15, 1995. (20)

10.40 Agreement for use and occupancy of a portion of 5 East Building, 95 Mayhill Street, Saddle Brook, New Jersey, between Chemaïd Laboratories, Inc. and

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

the Company dated February 9, 1996. (20)

(17) Incorporated by reference to the Company's report on Form 8-K (date of event - December 6, 1993), as amended by the Form 8, Amendment No. 1 to such Report.

(18) Incorporated by reference to the Company's report on Form 8-K (date of event - January 21, 1995).

(19) Incorporated by reference to the Company's report on Form 10-K for the year ended December 31, 1994.

(20) Incorporated by reference to the Company's report on Form 10-K for the year ended December 31, 1995.

31

10.41 Depository Agreement between Chemaid Laboratories, Inc. and the Company dated February 9, 1996. (20)

10.42 Consulting Agreement between Charles Fox Associates, Inc. and the Company dated February 5, 1996. (20)

10.43 First Amendment to Licensing Agreement dated May 31, 1996 between QVC and the Company, files as Exhibit 10.1 therein. (14)

10.44 Letter Agreement between QDirect, Inc. and Hydron Direct, Inc. dated May 31, 1996, filed as Exhibit 10.2 therein. (14)

10.45 Lease Agreement between Industrial Office Associates and the Company dated March 10, 1997. (21)

10.46 Sponsorship Agreement with Pro Player Stadium dated January 1, 1997. (21)

10.48 Executive Suite License Agreement dated March 4, 1997. (21)

10.49 Sponsorship Agreement with Miami Heat Limited Partnership and Sunshine Network dated December 1996. (21)

10.50 Consulting Agreement between Charles Fox Associates, Inc. and the Company dated May 20, 1997. (22)

10.51 Personal Appearance Agreement between Mr. Charles Fox and the Company dated May 20, 1997. (22)

10.52 Second Amendment to Licensing Agreement dated June 11, 1997 between QVC and the Company. (22)

10.53 Letter Agreement between QVC and the Company dated October 17, 1997. (22)

10.54 Consulting Agreement between Gloria Barton and the Company dated November 1, 1997. (22)

10.55 Service Agreement between Lauren Anderson and the Company dated January 1, 1998. (22)

10.56 Amendment to Employment Agreement between Richard Tauman and the Company dated August 13, 1998. (23)

10.57 Consulting Agreement between Richard Tauman and the Company dated December

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

1, 1998. (23)

10.58 Marketing and Distribution Agreement between Home Shopping Club LP and the Company dated September 1, 1999. (23)

(21) Incorporated by reference to the Company's report on Form 10-K for the year ended December 31, 1996.

(22) Incorporated by reference to the Company's report on Form 10-K for the year ended December 31, 1997.

32

Amendment to 1993 Nonemployee Director Stock Option Plan.24

1997 Nonemployee Director Stock Option Plan.24

21 Subsidiaries of the Registrant.

(b) Reports on Form 8-K

Current Report on Form 8-K (date of report July 12, 2000), dated June 29, 2000, reporting items 4 and 7.

Current Report on Form 8-K (date of report May 31, 2000), dated May 31, 2000, reporting items 4 and 7.

(23) Incorporated by reference to the Company's report on Form 8-K (date of report September 14, 1999), dated September 1, 1999.

(24) Incorporated by reference to the Company's Definitive Proxy Statement on Schedule 14A for the year ended December 31, 1996.

33

Report of Independent Certified Public Accountants

The Board of Directors and Shareholders
Hydron Technologies, Inc.

We have audited the accompanying consolidated balance sheet of Hydron Technologies, Inc. and subsidiaries (the Company) as of December 31, 1998 and 1997, and the related consolidated statements of operations, shareholders' equity and cash flows for each of the two years in the period ended December 31, 1998. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by Management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Hydron Technologies, Inc. and subsidiaries at December 31, 1998 and 1997, and the consolidated results of their operations and their cash flows for each of the two years in the period ended December 31, 1998, in conformity with generally accepted accounting principles.

/s/ ERNST & YOUNG LLP

West Palm Beach, Florida
March 5, 1999

34

Report of Independent Certified Public Accountants

The Board of Directors and Shareholders
Hydron Technologies, Inc.

We have audited the accompanying consolidated balance sheets of Hydron Technologies, Inc. and subsidiaries (the Company) as of December 31, 2000 and 1999 and the related consolidated statements of operations, shareholders' equity and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by Management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Hydron Technologies, Inc. and subsidiaries at December 31, 2000 and 1999, and the consolidated results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company experienced losses from operations in 2000, 1999, and 1998. These matters raise doubt about the Company's ability to continue as a going concern. Management has implemented direct marketing techniques to increase the more profitable Catalog sales, add new customers and take advantage of new channels of distribution (see note 13 to Consolidated Financial Statements). The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ DASZKAL BOLTON MANELA DEVLIN & CO.

Boca Raton, Florida
March 23, 2001

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

35

HYDRON TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	DECEMBER
	----- 2000 -----
ASSETS	
Current Assets	
Cash	\$ 190,946
Trade accounts receivable	136,306
Inventories	1,489,396
Prepaid expenses and other current assets	39,619

Total current assets	1,856,267
Property and equipment, less accumulated depreciation of \$931,232 and \$758,081 at December 31, 2000 and 1999, respectively	111,002
Deposits	60,403
Investment in joint venture	--
Deferred product costs, less accumulated amortization of \$5,194,952 and \$4,914,191 at December 31, 2000 and 1999, respectively	772,843

Total Assets	\$ 2,800,515 =====
LIABILITIES AND SHAREHOLDERS' EQUITY	
Current liabilities	
Accounts payable	\$ 194,791
Accrued liabilities	464,084

Total current liabilities	658,875
Commitments and contingencies	--
Shareholders' equity	
Common stock - \$.01 par value 30,000,000 shares authorized; 5,035,336 shares issued; and 4,975,136 shares outstanding	50,353
Additional paid-in capital	19,501,837
Accumulated deficit	(16,971,392)
Treasury stock, at cost; 60,200 shares	(439,158)

Total Shareholders' equity	2,141,640

Total liabilities and shareholders equity	\$ 2,800,515 =====

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

SEE ACCOMPANYING NOTES

36

HYDRON TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

	YEARS ENDED DECEMBER 31,		
	2000	1999	1998
Net sales	\$ 2,081,468	\$ 2,593,448	\$ 3,983,448
Cost of sales	450,478	1,237,816	1,590,448
Write down of inventory	--	794,362	442,448
Gross profit	1,630,990	561,270	1,950,552
Expenses			
Royalty expense	103,558	141,974	214,448
Research and development	84,108	211,956	350,448
Selling, general & administration	1,926,959	2,160,227	2,311,448
Employment contract settlement costs	--	620,099	627,448
Amortization of deferred product costs	287,395	290,740	309,448
Depreciation & amortization	175,741	200,463	204,448
Total expenses	2,577,761	3,625,459	4,018,448
Operating loss	(946,771)	(3,064,189)	(2,067,448)
Interest income	20,945	80,860	144,448
Equity in earnings of joint venture	2,194	9,187	40,448
Loss before income taxes	(923,632)	(2,974,142)	(1,882,448)
Income taxes expense	--	--	--
Net loss	\$ (923,632)	\$ (2,974,142)	\$ (1,882,448)
Basic and diluted loss per share			
Net loss per common share	\$ (0.19)	\$ (0.60)	\$ (0.60)
Weighted average number of shares outstanding (basic and diluted)	4,975,136	4,953,054	4,910,448

SEE ACCOMPANYING NOTES

37

HYDRON TECHNOLOGIES, INC. AND SUBSIDIARIES

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

	COMMON STOCK		ADDITIONAL PAID-IN CAPITAL	ACCUMULATED DEFICIT
	SHARES	AMOUNT		
Balance at December 31, 1997	4,960,336	\$ 49,603	\$ 19,429,931	\$(11,190,951)
Net loss	--	--	--	(1,882,667)
Balance at December 31, 1998	4,960,336	49,603	19,429,931	(13,073,618)
Issuance of common shares for service	75,000	750	71,906	--
Purchase of treasury shares, at cost (10,000 shares)	--	--	--	--
Net loss	--	--	--	(2,974,142)
Balance at December 31, 1999	5,035,336	50,353	19,501,837	(16,047,760)
Net loss	--	--	--	(923,632)
Balance at December 31, 2000	5,035,336	\$ 50,353	\$ 19,501,837	\$(16,971,392)

SEE ACCOMPANYING NOTES

38

HYDRON TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

	YEARS ENDED DECEMBER 31,		
	2000	1999	1998
OPERATING ACTIVITIES			
Net loss	\$ (923,632)	\$(2,974,142)	\$(1,882,667)
Adjustments to reconcile net loss to net cash provided (used) by operating activities			
Depreciation and amortization	463,136	491,203	511,203
Loss on disposal of equipment	--	55,216	--
Equity in earnings of joint venture	(2,194)	(9,187)	(4,187)
Cost of stock issued for services	--	72,656	--
Write down of inventory	--	794,362	44,362
Inventory purchase commitment	(175,000)	200,000	--
Change in operating assets and liabilities			
Trade accounts receivables	(97,816)	390,327	12,327
Inventories	(51,104)	(481,301)	60,301
Prepaid expenses and other current assets	78,834	(45,843)	5,843
Deposits	116,047	129,137	14,137

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

Accounts payable	67,248	(134,038)	(31)
Accrued liabilities	(3,404)	37,207	9
	-----	-----	-----
Net cash used by operating activities	(527,885)	(1,474,403)	(26)
 INVESTING ACTIVITIES			
Capital expenditures, net	--	--	(2)
Proceeds from liquidation of joint venture	64,915	--	27
Proceeds from sale of fixed assets	--	8,351	
	-----	-----	-----
Net cash provided by investing activities	64,915	8,351	25
 FINANCING ACTIVITIES			
Purchase of treasury stock	--	(7,813)	
	-----	-----	-----
Net cash used by financing activities	--	(7,813)	
	-----	-----	-----
Net decrease in cash and cash equivalents	(462,970)	(1,473,865)	(
Cash and cash equivalents at beginning of period	653,916	2,127,781	2,13
	-----	-----	-----
Cash and cash equivalents at end of period	\$ 190,946	\$ 653,916	\$ 2,12
	=====	=====	=====

See accompanying notes

39

Hydron Technologies, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, 2000, 1999 and 1998

1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

ORGANIZATION OF BUSINESS

Hydron Technologies, Inc. and subsidiaries (the "Company") sell consumer and professional products, primarily in the personal care/cosmetics field, directly to consumers through the Company's Hydron Catalog and Website. The Company also has a licensing agreement with Home Shopping Club LP ("HSN"), whereby HSN purchases the Company's products and takes physical possession of these products prior to HSN's sale of the products to the ultimate end user. The products are sold and shipped to the end user by HSN. The sales of the Company's products to HSN are sold under terms typical to HSN through its Master Terms and Conditions contract.

The Company also holds the exclusive license with National Patent Development Corporation ("National Patent") to a Hydron polymer-based drug delivery system for topically applied, nonprescription pharmaceutical products, which the Company intends to use to develop proprietary products or license to third parties.

BASIS OF PRESENTATION

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

The consolidated financial statements include the accounts of the Company and all subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The Company's investment in a joint venture is accounted for using the equity method of accounting.

The preparation of financial statements in conformity with generally accepted accounting principles requires Management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents includes \$76,651 not covered by the Federal Deposit Insurance Commission. The risk associated with these amounts is considered low due to the credit quality of the institutions.

The Company considers all highly liquid investments with a maturity of three months or less at the date of acquisition to be cash equivalents. The credit risk associated with cash equivalents is considered low due to the credit quality of the issuers of the financial instruments.

40

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

CONCENTRATION OF CREDIT RISK

Trade accounts receivable are due primarily from HSN and QVC, Inc. (QVC) which are usually paid to the Company within 30 days after HSN's and QVC's receipt of goods. The Company performs ongoing evaluations of its significant customers and does not require collateral.

INVENTORIES

Inventories are valued at the lower of cost (first-in, first-out) or market, and include finished goods, packaging and raw materials

LONG-LIVED ASSETS

Long-lived assets, consisting primarily of deferred product costs, are accounted for in accordance with Financial Accounting Standards Board ("FASB") Statement No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of." FASB Statement No. 121 requires impairment losses be recognized for long-lived assets when indicators of impairment are present and the undiscounted cash flows are not sufficient to recover the assets' carrying amount. The Company analyzes undiscounted cash flows on an annual basis. No impairment losses have been recognized in the three-year period ended December 31, 2000.

PROPERTY AND EQUIPMENT

Property and equipment, consisting primarily of office leasehold improvements, furniture and equipment, is carried at cost. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, ranging from four to six years (see Note 3).

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

DEFERRED PRODUCT COSTS

Deferred product costs consist primarily of costs incurred for the purchase and development of patents and product rights (see Note 4). The deferred product costs are being amortized over their estimated useful lives of eight to 20 years using the straight-line method.

41

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

COMMON STOCK, COMMON STOCK OPTIONS AND NET LOSS PER SHARE

On October 1, 1998, the Company's shareholders approved a one-for-five reverse stock split of the Company's Common Stock, which became effective on October 19, 1998. All share data and per share amounts have been adjusted to reflect the reverse stock split on a retroactive basis.

When the Company issues shares of common stock in exchange for services, an expense is recognized over the period in which the services are rendered based upon the fair value of such shares at the date such arrangements are consummated or authorized by the Board of Directors, with a corresponding credit to capital.

The Company has elected to follow Accounting Principles Board (APB) Opinion No. 25, "Accounting for Stock Issued to Employees," and related Interpretations in accounting for its stock options and has adopted the disclosure-only provisions of FASB Statement No. 123, "Accounting and Disclosure of Stock-Based Compensation." Accordingly, no compensation cost has been recognized for the Company's stock option plans.

REVENUE RECOGNITION AND PRODUCT WARRANTY

Revenue from product sales is recognized at the time of shipment. Provision is made in the period of the sale for estimated product returns from the ultimate end user.

RESEARCH AND DEVELOPMENT

Research and development costs are charged to operations when incurred and are included in operating expenses.

ADVERTISING

Advertising costs are expensed as incurred and are included in "selling, general and administrative expenses." Advertising expenses amounted to approximately \$140,000, \$263,000, and \$112,000 for 2000, 1999, and 1998, respectively.

42

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

2. FAIR VALUE OF FINANCIAL INSTRUMENTS

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

The carrying value of cash, accounts receivables, deposits, accounts payable and other payables approximates fair value because of their short maturities.

3. EMPLOYMENT CONTRACT SETTLEMENT

For the years' ended December 31, 1999, and 1998, the Company recorded charges of \$620,099, and \$627,713, respectively, for the settlement and associated legal fees regarding three employment contracts. These contracts, which originated during 1993 and 1994, overburdened the Company's operations during a transition period when Company's revenues could not support the contracts. The Company does not currently have any employment contracts, and did not incur any related expenses for the year ended December 31, 2000.

4. RECLASSIFICATION

Certain amounts previously reported for 1999 and 1998 have been reclassified to conform to the classification used in 2000. Such reclassifications had no effect on the reported net loss.

5. INVENTORIES

At December 31, 2000 and 1999, inventories consist of the following:

	2000	1999
	-----	-----
Finished goods	\$ 869,082	\$ 753,692
Raw materials and components	629,314	684,600
	-----	-----
	\$1,489,396	\$1,438,292
	=====	=====

The results of operations include charges of \$794,362, and \$442,254 for the years ended December 31, 1999 and 1998, respectively. These charges relate primarily to the write-down, to net realizable value, of components and finished goods of products that the Company does not plan to promote in the future, which consist mainly of products outside of the traditional skin care product line, such as hair care, sun care, bath and body products and other products.

Although these write-downs have been abnormally high due to the changes in distribution channels and packaging, Management believes that some inventory obsolescence and revitalized packaging is an annual cost of producing revenue growth in this industry.

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

6. PROPERTY AND EQUIPMENT

At December 31, 1999 and 1998, property and equipment consist of the following:

	2000	1999
	-----	-----
Furniture and equipment	\$ 573,982	\$ 576,572
Leasehold improvements	468,252	468,252
	-----	-----
	1,042,234	1,044,824
Less accumulated depreciation	(931,232)	(758,081)

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

-----	-----
\$ 111,002	\$ 286,743
=====	=====

7. DEFERRED PRODUCT COSTS AND ROYALTY AGREEMENTS

From 1976 through 1989, the Company and National Patent entered into various agreements, wherein the Company obtained the exclusive worldwide rights to market products using Hydron polymers in the consumer and oral health fields, the two fields in which the Company has concentrated its research and development efforts, and to utilize the Hydron polymer as a drug release mechanism in topically applied, nonprescription pharmaceutical products. The Hydron polymer is the underlying technology in substantially all of the Company's products. National Patent has the exclusive worldwide rights to market prescription drugs and medical devices using Hydron polymers. Further, each has the right to exploit products with Hydron polymers not in the other's exclusive fields. As consideration for product rights obtained, the Company issued National Patent an aggregate of 220,000 shares of common stock through 1989, valued at \$5,370,000. The valuation for these shares was based on the market prices of the Company's common stock at the dates the agreements were made.

The agreements require the Company to pay a 5% royalty to National Patent based on the net sales of products containing the Hydron polymer. Additionally, National Patent is required to pay the Company a 5% royalty on its net sales of Hydron polymer-based products, except with respect to certain excluded products. In the area of prescription and nonprescription drugs using Hydron polymers as a drug release mechanism, both the Company and National Patent have agreed to pay the other a royalty equal to 5% of net sales received from third parties with regard to such products developed. In addition, each will pay the other 25% of any up-front license fees, royalties or similar payments received from third parties with regard to such products developed in the area of nonprescription drugs.

44

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

7. DEFERRED PRODUCT COSTS AND ROYALTY AGREEMENTS (CONTINUED)

For the years ended December 31, 2000, 1999, and 1998, the Company incurred royalties payable to National Patent of approximately \$103,000, \$130,000, and \$190,000, respectively. The Company has not received any royalties from National Patent during these periods.

8. INVESTMENT IN JOINT VENTURE

During 1995, the Company entered into an agreement with QVC and another company to form a joint venture known as Hydromercial Partners (the "Joint Venture"). The purpose of the Joint Venture was to provide and sell the Company's Hydron polymer-based skin care line by means of a thirty (30) minute commercial ("Infomercial") which the Joint Venture produced. As of March 31, 2000, the Joint Venture discontinued operations and was dissolved during the year ended December 31, 2000. The Company has received inventory and 50% of the proceeds from liquidation. The amount realized exceeded the carrying value in the balance sheet by \$2,194, which is reflected in the 2000 operating statement.

9. SIGNIFICANT CUSTOMER

The Company presently sells a substantial portion of its products to HSN and

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

QVC. The percent of Company's sales for the years ended December 31, 2000, 1999, and 1998 and trade receivable balances as of December 31, 2000, 1999, and 1998 are as follows:

	2000 -----	1999 -----	1998 -----
Percent of Sales			
HSN	32%	25%	--
QVC	18%	43%	79%
Trade Receivables			
HSN	\$ 97,186	\$ 34,743	--
QVC	\$ 44,120	\$ 3,747	\$427,000

The Company entered into a license agreement with QVC, Inc. ("QVC License Agreement") in 1993, whereby QVC was granted exclusive rights to market and distribute the Company's proprietary consumer products using Hydron polymers in the Western Hemisphere. In 1996, the Company and QVC modified the QVC License Agreement ("Amended License Agreement"), whereby the Company reacquired certain retail marketing rights to the Hydron product line. Such retail marketing rights included prestige retail channels of distribution such as traditional department and specialty stores, boutique stores and beauty salons, as well as catalog sales. QVC was entitled to receive a commission from the Company on any such sales.

45

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

9. SIGNIFICANT CUSTOMER (CONTINUED)

In addition, the Amended License Agreement increased the minimum product purchase requirements QVC was required to meet, on an annual basis over a two-year term ended May 31, 1998, to maintain its exclusive rights to market Hydron consumer products in the Western Hemisphere, through all channels of distribution except as noted above. QVC did not meet the annual minimum product purchase requirements to maintain exclusivity for the year ended May 31, 1997.

On June 11, 1997, the Company and QVC renegotiated the Amended License Agreement ("Renegotiated License Agreement") pursuant to which the term of the Amended License Agreement was extended to May 31, 1999. Under the terms of the Renegotiated License Agreement, QVC was required to meet certain minimum product purchase requirements during each two-year period during the term of the agreement, as well as annual minimum product purchase requirements, to maintain its exclusive rights. No obligation existed for QVC to purchase the Company's product, except to maintain such exclusive rights, and no assurances could be given that QVC would meet the escalating minimum purchase levels for subsequent years in order to maintain such exclusive rights. If QVC had met the stipulated minimum product purchase requirements, then the Renegotiated License Agreement would have renewed automatically. If QVC did not meet the annual minimum product purchase requirements, the Company could elect to continue or terminate the Renegotiated License Agreement as of the end of each contract year during the term.

Although QVC did not satisfy the minimum product purchase requirements for the period ended May 31, 1998, the Company elected to continue the Renegotiated License Agreement at that time. Effective May 31, 1999, the Company terminated the Renegotiated License Agreement as a result of QVC's failure to satisfy the annual minimum product purchase requirements for the period ended May 31, 1999. Under the terms of the Renegotiated License Agreement, QVC had a period of 30

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

days, commencing with the Company's notice to QVC of its decision to terminate, to satisfy the minimum product purchase requirements. As the deficiency was not cured during that time, the Renegotiated License Agreement terminated May 31, 1999. Under the terms of the Renegotiated License Agreement, following termination thereof, the Company could not market or sell certain Hydron products through direct response television in the Western Hemisphere, for a period of three months ending September 1, 1999.

The Company continues to sell certain product to QVC, on a non-exclusive basis, so that QVC can resell these products to their customers who had previously purchased and wish to re-order Hydron products.

46

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

9. SIGNIFICANT CUSTOMER (CONTINUED)

Effective September 1, 1999, the Company entered into a marketing and distribution agreement (the "Home Shopping Agreement") with HSN, that grants HSN an exclusive worldwide license to market and distribute certain of the Company's proprietary consumer products through various forms of electronic retailing. The Home Shopping Agreement also grants HSN a non-exclusive license to market Hydron products through all other methods of distribution in certain countries outside the United States.

Under the terms of the Home Shopping Agreement, HSN would make minimum product purchases i) during the period ending 12 months following the date on which the products first aired on HSN's television programs, and ii) during the second 12 months following the date of the first airing (the "Initial Term"). Should HSN have exceeded a certain threshold amount in retail sales of Hydron products to consumers during the Initial Term, the term of the Home Shopping Agreement could be automatically renewed after the Initial Term for an indefinite number of successive one-year periods, subject to HSN's having achieved certain escalating threshold levels in product purchases. However, beginning in the third contract year, HSN would no longer be required to make minimum product purchases, except to maintain exclusivity.

The Company launched its products on HSN's television network on September 16, 1999. Hydron products have since been featured in "Hydron Skin Care Solutions" hours. In addition to selling Hydron products on-air, HSN provides brand development, and marketing promotion and support for the products, including direct mail, sampling, outbound telemarketing, package inserts, advertising and publicity programs, the costs and expenses of which are shared equally by HSN and the Company.

HSN did not meet the minimum purchase requirements during the first year of the two-year agreement. Therefore the contract does not automatically renew after the Initial Term. Management is currently conducting discussions with HSN to resolve the first year shortfall and revised terms for HSN to maintain its exclusivity. Although Management is optimistic of achieving a successful conclusion, a favorable result is not certain.

10. INCOME TAXES

The Company accounts for income taxes under FASB Statement No. 109, "Accounting for Income Taxes" (FASB 109). Deferred income tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

that will be in effect when the

47

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

10. INCOME TAXES (CONTINUED)

differences are expected to reverse. There has been no income tax expense during the three years ended December 31, 2000, 1999, and 1998.

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's net deferred income taxes are as follows:

	2000	1999	1998
Net operating loss carryforwards	\$ 7,135,000	\$ 6,478,000	\$ 5,414,000
Tax credit carryforwards	180,000	180,000	215,000
Other	575,000	951,000	819,000
Deferred tax assets	7,890,000	7,609,000	6,448,000
Less valuation allowance	(7,890,000)	(7,609,000)	(6,448,000)
Total net deferred taxes	\$ --	\$ --	\$ --

FASB 109 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, Management has determined that a \$7,890,000 valuation allowance at December 31, 2000 is necessary to reduce the deferred tax assets to the amount that will more likely than not be realized. The valuation allowance increased by \$281,000, \$1,161,000, and \$909,000 in 2000, 1999 and 1998, respectively. At December 31, 2000, the Company has available net operating loss carryforwards of \$18,778,000, which will expire beginning in the year 2002 and through the year 2015. The tax benefit relating to \$2,745,000 of the above net operating loss carryforwards will be charged to shareholders' equity in the period in which the benefit is recognized.

The reconciliation of income tax rates, computed at the U.S. federal statutory tax rates, to income tax expense is as follows:

	YEARS ENDED DECEMBER 31,		
	2000	1999	1998
Tax at U.S. statutory rates	34%	34%	34%
State income taxes, net of federal tax benefit	4	4	4
Valuation allowance adjustments	(38)	(38)	(38)
	-0-%	-0-%	-0-%

48

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

11. STOCK OPTIONS AND WARRANTS

The number of shares of common stock reserved for issuance at December 31, 2000 and 1999 was 411,100.

1989 STOCK OPTION PLAN

Under the 1989 Stock Option Plan, the Company may grant incentive stock options, nonqualified stock options and/or stock appreciation rights to key employees, officers, directors and consultants of the Company, and its present and future subsidiaries to purchase an aggregate of 200,000 shares of the Company's common stock.

These options expire five years from the date of the grant. There are no outstanding options at December 31, 2000. There are 12,100 options available for grant under this plan at December 31, 2000.

1993 STOCK OPTION PLAN

Under the 1993 Stock Option Plan, the Company may grant incentive stock options, nonqualified stock options and/or stock appreciation rights to key employees, officers, directors and consultants of the Company to purchase an aggregate of 200,000 shares of the Company's common stock.

These options expire five years from the date of the grant and all but 2,000 of the outstanding options are exercisable at December 31, 2000. There are no options available for grant under this plan at December 31, 2000.

1993 NONEMPLOYEE DIRECTOR STOCK OPTION PLAN

The 1993 Nonemployee Director Stock Option Plan provides grants of stock options to nonemployee directors of the Company to purchase an aggregate of 50,000 shares of the Company's common stock.

These options expire five years from the date of the grant and all outstanding options are exercisable at December 31, 2000. There are 14,000 options available for grant under this plan at December 31, 2000.

1997 NONEMPLOYEE DIRECTOR STOCK OPTION PLAN

During 1997, the Company adopted the 1997 Nonemployee Director Stock Option Plan. Such plan provides grants of stock options to nonemployee directors of the Company to purchase an aggregate of 100,000 shares of the Company's common stock. Each

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

11. STOCK OPTIONS AND WARRANTS (CONTINUED)

1997 NONEMPLOYEE DIRECTOR STOCK OPTION PLAN (CONTINUED)

nonemployee director shall be granted an option to purchase 2,000 shares of the Company's common stock on each May 1st throughout the term of this plan at

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

exercise prices equal to the average of the fair market value of the Company's common stock during the ten business days preceding the date of the grant. In addition, each nonemployee director who sits on a committee of the Board of Directors shall be granted an option to purchase 500 shares of the Company's common stock under the same pricing arrangements as above. Subject to certain exceptions, no options granted under this plan shall be exercisable until one year after the date of grant.

During August 1999, the Company agreed to grant an option to purchase 18,000 shares of the Company's common stock to each of the five individuals comprising the Board of Directors, subject to shareholders' approval at the next annual meeting, at an exercise price of \$.64065 per share. Since the options have been granted pending shareholders' approval, the options are reflected as outstanding as of December 31, 1999.

These options expire five years from the date of grant and all but 6,000 of the outstanding options are exercisable at December 31, 2000. There are 47,500 options available for grant under this plan at December 31, 2000.

Activity with respect to these plans is as follows:

	NUMBER OF OPTIONS/ WARRANTS	PRICE PER SHARE	WEIGHTED AVERAGE EXERCISE PRICE
	-----	-----	-----
Outstanding at December 31, 1997	80,700	3.02 to 28.44	14.18
Stock options granted	15,500	.53 to 2.42	.68
Stock options expired	(14,000)	.53 to 12.50	12.14

Outstanding at December 31, 1998	82,200	.53 to 28.44	12.00
Stock options granted	199,500	.64 to .92	.74
Stock options expired	(41,700)	.53 to 28.44	15.24

Outstanding at December 31, 1999	240,000	.53 TO 23.91	2.06
Stock options granted	8,000	.37	.37
Stock options expired	(60,500)	.64 TO 23.91	4.05

Outstanding at December 31, 2000	187,500	.37 TO 12.50	1.34
	=====		

50

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

11. STOCK OPTIONS AND WARRANTS (CONTINUED)

OTHER OPTIONS AND WARRANTS

The Company has agreements with several consultants who are to provide financial, business and technical advice to the Company in connection with the research, development, marketing and promotion of its products and other matters. In exchange, these consultants were granted warrants and nonqualified stock options to purchase shares of the Company's common stock at prices representing the fair market value of the shares at the date of grant. Activity with respect to options and warrants granted to these consultants is summarized below:

	NUMBER OF OPTIONS/ WARRANTS	PRICE	WEIGHTED AVERAGE EXERCISE
	-----	-----	-----

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

	WARRANTS	PER SHARE	PRICE
	-----	-----	-----
Outstanding at December 31, 1997	112,000	12.50 to 25.00	13.84
Stock options expired	(10,000)	12.50	12.50

Outstanding at December 31, 1998	102,000	13.75 to 25.00	13.97
Stock options granted	50,000	2.50	2.50
Stock options expired	(2,000)	25.00	25.00

Outstanding at December 31, 1999 and 2000	150,000	2.50 TO 25.00	10.17
	=====		

The options and warrants outstanding at December 31, 2000 expire two to five years after the date of grant. At December 31, 2000, all outstanding options and warrants are exercisable.

Pro forma information regarding net income and earnings per share is required by FASB Statement No. 123, which also requires that the information be determined as if the Company had accounted for its stock options granted subsequent to December 31, 1994 under the fair value method of that Statement. The fair value for these options was estimated at the date of the grant using a Black-Scholes option pricing model with the following weighted-average assumptions for the years ended December 31, 2000, 1999, and 1998:

	2000	1999	1998
	-----	-----	-----
Risk-free interest rate	6.0%	6.0%	6.5%
Expected life	3 YEARS	3 years	3 years
Expected volatility	702%	825%	757%
Expected dividend yield	0%	0%	0%

51

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

11. STOCK OPTIONS AND WARRANTS (CONTINUED)

The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because the Company's stock options have characteristics significantly different than those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in Management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its stock options.

For purposes of the pro forma disclosures, the estimated fair value of the options is amortized to expense over the options' vesting period. The effect of compensation expense from stock option awards on proforma net income reflects only the vesting of 1998, 1997, 1996 and 1995 awards in 1998, the vesting of 1999, 1998, 1997, 1996 and 1995 awards in 1999, and the vesting of 2000, 1999, 1998, 1997, 1996, and 1995 awards in 2000 in accordance with Statement No. 123. Because compensation expense associated with the stock option award is recognized over the vesting period, the initial impact of applying Statement No. 123 may not be indicative of compensation expense in future years, when the effect of the amortization of multiple awards will be reflected in pro forma net

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

income. The effect of Statement No. 123 resulted in a pro forma net loss of \$925,152, \$3,015,082, and \$1,911,068 for the years ended December 31, 2000, 1999, and 1998, respectively. In addition, the pro forma net loss per share was \$.19, \$.61, and \$.39 per share for the years ended December 31, 2000, 1999, and 1998, respectively.

The weighted average grant-date fair value of options granted during the year ended December 31, 2000 was \$.19 for options whose exercise price was equal to the market price on the date of the grant. There were no options granted during the year ended December 31, 2000 whose exercise price was greater than or less than the market price on the date of the grant. The weighted average remaining contractual life of all options outstanding at December 31, 1999 was 2.0 years.

52

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

12. RELATED PARTY TRANSACTIONS

During 1997, the Company hired a director as a marketing consultant, who was paid approximately \$43,000, \$48,000 and \$21,000 for the years ended December 31, 1999, 1998 and 1997, respectively. This consulting relationship ended in December 1999.

The Company has also paid a consultant, who was a director from September 1997 to October 1998, advisory fees, quality control and product testing expense reimbursements of approximately \$63,000, \$130,000, and \$101,000 during the years ended December 31, 2000, 1999, and 1998, respectively. Although the contract has expired, Management has continued this agreement on a month-to-month basis.

The Company sells products to any of the Company's shareholders at a 25% discount. This discount is designed to acknowledge the appreciation of the shareholders support and to promote the use of the products.

13. COMMITMENTS

The Company leases office space under a noncancelable lease agreement, which expires in September 2001. In April 1999, the Company subleased a portion of its office space to unrelated third parties under a noncancelable sublease agreement under terms similar to the original lease. The sublease resulted in a reduction of rent expense of approximately \$31,000 in 2000. At December 31, 2000, the future minimum rental payments due under this noncancelable lease are \$55,000.

Net rent expense was approximately \$185,000, \$226,000, and \$269,000 in 2000, 1999, and 1998, respectively.

14. MANAGEMENT'S PLAN

The Company has incurred significant losses over the past five years. The ability of the Company to continue as a going concern is dependent on increasing sales while managing operating expenses.

Management's plan to increase sales and reduce operating expenses includes several specific actions. Catalog sales will continue to be emphasized since they have higher profit margins and represent markets for the Company that are growing more rapidly than the Company's traditional television market. Direct marketing techniques will be used to reach new and current consumers such as promotions mailed to targeted

Hydron Technologies, Inc.

Notes to Consolidated Financial Statements (continued)

14. MANAGEMENT'S PLAN (CONTINUED)

Consumers, Web site specials, promotions to other Web site customers, and direct e-mail promotions to new customers.

The Company will make every effort to expand its television sales presence with HSN and HSE. The Company is negotiating with HSN to set a schedule of show hours that will allow for the organized development of new products appropriate to the venue.

In addition, the Company has added a significant Private Label customer of Hydron based formulas with a proprietary nutritional complex of additives that will begin ordering in second quarter, 2001. This customer competes in the Multi-Level Marketing category and has been successful for 13 years.

The Company is also pursuing international distribution agreements that will expand the company's distribution around the world. Finally, the Company will continue to develop proprietary technology that it believes will improve its long-term success in the category.

Based on the above plan and the Company's present cash position, the absence of any short or long term debt, arrangements with third parties for contractual manufacturing and R&D, and the Company's present business strategy, Management believes that the Company has adequate resources to meet normal, recurring obligations, for at least the next twelve months, as they become due. Further, in view of the payment terms in connection with sales to HSN, Management does not anticipate any difficulty in financing foreseeable inventory requirements.

There can be no assurances that Management's Plan will be successful and the Company's actual results could differ materially. No estimate has been made should Management's plan be unsuccessful.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

HYDRON TECHNOLOGIES, INC.
(Registrant)

By: /s/ RICHARD BANAKUS

Richard Banakus, Interim President

Date: April 2, 2001

Pursuant to the requirements of the Securities Exchange Act of 1934,

Edgar Filing: HYDRON TECHNOLOGIES INC - Form 10-K

this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated:

By: /s/ RICHARD BANAKUS

Richard Banakus,
Chairman of the Board
(principal executive officer)
Date: April 2, 2001

By: /s/ WILLIAM A FAGOT

William A. Fagot
(principal financial and
accounting officer)
Date: April 2, 2001

By: /s/ JOSHUA ROCHLIN

Joshua Rochlin, Director
Date: April 2, 2001

By: /s/ KAREN GRAY

Karen Gray, Director
Date: April 2, 2001

By: /s/ CHARLES JOHNSTON

Charles Johnston, Director
Date: April 2, 2001